CN106068127B - 蛋白质的硫醚缀合方法 - Google Patents
蛋白质的硫醚缀合方法 Download PDFInfo
- Publication number
- CN106068127B CN106068127B CN201480068335.5A CN201480068335A CN106068127B CN 106068127 B CN106068127 B CN 106068127B CN 201480068335 A CN201480068335 A CN 201480068335A CN 106068127 B CN106068127 B CN 106068127B
- Authority
- CN
- China
- Prior art keywords
- protein
- chemical moiety
- conjugation
- solution
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13197150 | 2013-12-13 | ||
| EP13197150.9 | 2013-12-13 | ||
| PCT/EP2014/077777 WO2015086853A1 (en) | 2013-12-13 | 2014-12-15 | Method for thioether conjugation of proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106068127A CN106068127A (zh) | 2016-11-02 |
| CN106068127B true CN106068127B (zh) | 2020-06-19 |
Family
ID=49765887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480068335.5A Active CN106068127B (zh) | 2013-12-13 | 2014-12-15 | 蛋白质的硫醚缀合方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11219690B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3079722B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6603662B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106068127B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2869309T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015086853A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117106085A (zh) | 2015-12-23 | 2023-11-24 | 美国安进公司 | 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法 |
| EP4480537A3 (en) | 2017-01-17 | 2025-03-12 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| CA3062194A1 (en) | 2017-06-20 | 2018-12-27 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
| JP7250706B2 (ja) | 2017-06-21 | 2023-04-03 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 |
| MA68842B1 (fr) * | 2017-08-04 | 2025-01-31 | Amgen Inc. | Procédé de conjugaison de cys-mabs |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210400C (zh) * | 1999-01-14 | 2005-07-13 | 博尔德生物技术公司 | 制备含游离半胱氨酸残基的蛋白质的方法 |
| WO2006134173A2 (en) * | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| CN101212984A (zh) * | 2005-07-06 | 2008-07-02 | Ucb医药有限公司 | 连接效应分子与蛋白质的方法 |
| CN103002918A (zh) * | 2010-01-22 | 2013-03-27 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| CN103087183A (zh) * | 2013-01-17 | 2013-05-08 | 南京邮电大学 | 一种光激发蛋白质中二硫键还原得到自由巯基的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| NZ522847A (en) | 2000-05-16 | 2004-11-26 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| WO2004101597A2 (en) | 2003-05-13 | 2004-11-25 | Frutarom Ltd. | Methods for the reduction of disulfide bonds |
| EP2033662B1 (en) | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| WO2007109475A2 (en) * | 2006-03-16 | 2007-09-27 | Bracco Imaging S.P.A. | Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines |
| JP5703020B2 (ja) | 2007-08-24 | 2015-04-15 | ノボ ノルディスク ヘルス ケア アーゲー | タンパク質を選択的に修飾するための組成物と方法 |
| RU2012134974A (ru) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированное соединение гормона роста |
| ES2582590T3 (es) | 2010-02-16 | 2016-09-13 | Novo Nordisk A/S | Método de purificación |
| CN103269720A (zh) | 2010-07-22 | 2013-08-28 | 诺沃—诺迪斯克保健股份有限公司 | 生长激素缀合物 |
| EP3412314A1 (en) | 2011-05-27 | 2018-12-12 | Baxalta GmbH | Therapeutic proteins conjugated to polysialic acid and methods of preparing same |
| KR20140091721A (ko) * | 2011-11-02 | 2014-07-22 | 제넨테크, 인크. | 오버로드 및 용리 크로마토그래피 |
-
2014
- 2014-12-15 EP EP14818938.4A patent/EP3079722B1/en active Active
- 2014-12-15 JP JP2016538783A patent/JP6603662B2/ja active Active
- 2014-12-15 US US15/103,482 patent/US11219690B2/en active Active
- 2014-12-15 ES ES14818938T patent/ES2869309T3/es active Active
- 2014-12-15 WO PCT/EP2014/077777 patent/WO2015086853A1/en not_active Ceased
- 2014-12-15 CN CN201480068335.5A patent/CN106068127B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210400C (zh) * | 1999-01-14 | 2005-07-13 | 博尔德生物技术公司 | 制备含游离半胱氨酸残基的蛋白质的方法 |
| WO2006134173A2 (en) * | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| CN101212984A (zh) * | 2005-07-06 | 2008-07-02 | Ucb医药有限公司 | 连接效应分子与蛋白质的方法 |
| CN103002918A (zh) * | 2010-01-22 | 2013-03-27 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| CN103087183A (zh) * | 2013-01-17 | 2013-05-08 | 南京邮电大学 | 一种光激发蛋白质中二硫键还原得到自由巯基的方法 |
Non-Patent Citations (1)
| Title |
|---|
| "Technology trends in antibody purification";Pete Gagnon;《 J. Chromatogr. A》;20111020;第1221卷;第57-70页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6603662B2 (ja) | 2019-11-06 |
| EP3079722A1 (en) | 2016-10-19 |
| WO2015086853A1 (en) | 2015-06-18 |
| US11219690B2 (en) | 2022-01-11 |
| ES2869309T3 (es) | 2021-10-25 |
| US20160303248A1 (en) | 2016-10-20 |
| EP3079722B1 (en) | 2021-03-24 |
| CN106068127A (zh) | 2016-11-02 |
| JP2017501148A (ja) | 2017-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI113272B (fi) | Parannettu proteiinien laskostamismenetelmä | |
| Liebner et al. | Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra | |
| JP6603662B2 (ja) | タンパク質のチオエーテルコンジュゲーション方法 | |
| ES2870802T3 (es) | Métodos de replegado de proteínas a elevado pH | |
| WO1999033988A1 (en) | A process for preparing human proinsulin | |
| ES2813501T3 (es) | Métodos de replegado de proteínas basados en filtración de flujo tangencial | |
| CN104926924A (zh) | 一种利用手性锍盐侧链稳定多肽α-螺旋二级结构的方法 | |
| CN103923209A (zh) | 一种Lambda干扰素突变体及聚乙二醇衍生物 | |
| CN101173006B (zh) | 一种重组人胰岛素的制备方法 | |
| CN105732820A (zh) | 一种重组人胰岛素原融合蛋白的复性方法 | |
| JP2017501148A5 (cg-RX-API-DMAC7.html) | ||
| CN108610415A (zh) | 一种抗体复合物的制备方法 | |
| JP4088584B2 (ja) | 融合タンパク質から目的タンパク質を分離する方法。 | |
| CN105085658A (zh) | 一种白细胞介素29突变体及聚乙二醇衍生物 | |
| CN100387614C (zh) | 包涵体蛋白复性并同时纯化的方法 | |
| JP2022511951A5 (cg-RX-API-DMAC7.html) | ||
| CN106632588A (zh) | 一种聚乙二醇修饰蛋白的纯化工艺 | |
| CN100493615C (zh) | 一种单修饰的聚乙二醇化胰岛素及其制备方法 | |
| CN104945498A (zh) | 长效化PEG-rExendin-4改构体偶联物的制备 | |
| CN100589844C (zh) | 一种单修饰的聚乙二醇-胰岛素复合物及其制备方法 | |
| CN118451086A (zh) | 一种蛋白和/或多肽糖基化修饰的方法 | |
| JP5713006B2 (ja) | チオスルホナート化合物、タンパク質及び/又はペプチドの可逆的カチオン化剤並びに可溶化方法 | |
| CN103333238A (zh) | 一种mPEG-MAL-aGLP-1复合物 | |
| CN115651070B (zh) | 链间二硫键CysA24-CysB23替代为硫醚键的H2 Relaxin衍生物 | |
| CN102585012B (zh) | 一种石斑鱼α干扰素衍生物的制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |